NEW YORK, Sep 17, 2019 (GLOBE NEWSWIRE via COMTEX) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Netflix, Inc. (nasdaqgs:NFLX)
Class Period: April 17, 2019 - July 17, 2019
Lead Plaintiff Deadline: September 20, 2019
Join the action: https://www.zlk.com/pslra-1/netflix-inc-loss-form?wire=3
Allegations: Netflix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.
To learn more about the Netflix, Inc. class action contact firstname.lastname@example.org.
Karyopharm Therapeutics Inc (nasdaqgs:KPTI)
Class Period: on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm's common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company's public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company's public offering of common stock conducted on or around May 7, 2018.
Lead Plaintiff Deadline: September 23, 2019
Allegations: Karyopharm Therapeutics Inc made materially false and/or misleading statements throughout the class period and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile," and assured investors that it was "well tolerated" by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
To learn more about the Karyopharm Therapeutics Inc class action contact email@example.com.
GTT Communications, Inc. /zigman2/quotes/203886362/composite GTT -0.28%
Class Period: February 26, 2018 - July 1, 2019
Lead Plaintiff Deadline: September 30, 2019
Join the action: https://www.zlk.com/pslra-1/gtt-communications-inc-loss-form?wire=3
Allegations: GTT Communications, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) following GTT's acquisition of Interoute Communications Holdings S.A., there were delays in migrating Interoute's legacy systems and processes into GTT's client management database system; (2) Interoute had made a strategic priority shift to sell cloud services that was a higher percentage of Interoute's sales in the two years leading up to the acquisition; (3) a material percentage of the Interoute sales representatives were not productive at selling GTT's core cloud networking services; (4) GTT was unable to yield as many Interoute salespeople because Interoute had hired many sales people focused on cloud services and allowed underperforming sales representatives to remain at Interoute; and (5) as a result of the foregoing, Defendants' public statements were materially false and/or misleading and/or lacked a reasonable basis.